Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03773107 · OUTCOME

Time to Best Response

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma · Source last updated 2025-01-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
Approximately 180 days after treatment start (disease assessment occurred after every 28-day cycle)

What was measured

Time to best response will be defined as the time from initiation of ruxolitinib treatment to the time of best objective status assessment of response.

Analysis population: Time to best response calculated only for participants who achieved a PR or better.

Groups in this outcome

Phase I 5 mg Ruxolitinib

Cohort 1) 5mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

Phase I 10 mg Ruxolitinib

Cohort 2) 10mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

Phase I 15 mg Ruxolitinib

Cohort 3) 15mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase I 5 mg Ruxolitinib0
Phase I 10 mg Ruxolitinib2
Phase I 15 mg Ruxolitinib1

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Phase I 10 mg Ruxolitinib3.2Not reported1.84.6Not reported
Phase I 15 mg Ruxolitinib2.1Not reported2.12.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG001
        lower Limit
        1.8
        upper Limit
        4.6
        value
        3.2
      2. group Id
        OG002
        lower Limit
        2.1
        upper Limit
        2.1
        value
        2.1
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      2
    3. group Id
      OG002
      value
      1
    units
    Participants
description
Time to best response will be defined as the time from initiation of ruxolitinib treatment to the time of best objective status assessment of response.
dispersion Type
Full Range
groups
  1. description
    Cohort 1) 5mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid
    id
    OG000
    title
    Phase I 5 mg Ruxolitinib
  2. description
    Cohort 2) 10mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid
    id
    OG001
    title
    Phase I 10 mg Ruxolitinib
  3. description
    Cohort 3) 15mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid
    id
    OG002
    title
    Phase I 15 mg Ruxolitinib
param Type
MEDIAN
population Description
Time to best response calculated only for participants who achieved a PR or better.
reporting Status
POSTED
time Frame
Approximately 180 days after treatment start (disease assessment occurred after every 28-day cycle)
title
Time to Best Response
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice